Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma

NCT01964430 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01964430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01964430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2014
Completion date
June 30, 2022
Enrollment
866 (actual)
Sites
341

Conditions

As the registry lists them; a condition with its own page is linked.

antimetabolites, antineoplastic, digestive system diseases, digestive system neoplasms, endocrine gland neoplasms, endocrine system diseases, gemcitabine, neoplasms, neoplasms by site, pancreatic diseases, pancreatic neoplasms